Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer.

MLA

Bryant, Alex K., et al. “Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-Small Cell Lung Cancer.” International Journal of Radiation Oncology, Biology, Physics, vol. 113, no. 1, May 2022, pp. 60–65. EBSCOhost, https://doi.org/10.1016/j.ijrobp.2021.12.176.

APA

Bryant, A. K., Sankar, K., Strohbehn, G. W., Zhao, L., Elliott, D., Daniel, V., Ramnath, N., & Green, M. D. (2022). Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 113(1), 60–65. https://doi.org/10.1016/j.ijrobp.2021.12.176

Chicago

Bryant, Alex K., Kamya Sankar, Garth W. Strohbehn, Lili Zhao, David Elliott, Victoria Daniel, Nithya Ramnath, and Michael D. Green. 2022. “Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-Small Cell Lung Cancer.” International Journal of Radiation Oncology, Biology, Physics 113 (1): 60–65. doi:10.1016/j.ijrobp.2021.12.176.